Strategic Partnerships Privately funded San Diego medtech with FDA Breakthrough Device designation history and active leadership updates presents opportunities to partner with larger sleep and respiratory care players seeking innovative airway management solutions.

Clinical Validation Evidence focus through pivotal SUPRA study updates and ongoing conference presentations signals strong clinical data potential; sales outreach should target hospitals and outpatient centers needing proven alternatives to CPAP.

Expansion Readiness Recent board addition and active participation in major healthcare conferences indicate readiness to scale; target distributors and regional sales reps in U.S. and international markets aligned with sleep medicine.

Market Positioning AerSleep and aer+ negative pressure airway technology addresses CPAP intolerance niche; identify clinics serving CPAP failures and sleep labs seeking non-invasive, well-tolerated options.

Financial Leverage Revenue in low to mid eight figures with $29M funding suggests budget capacity for pilot programs, value-based contracts, and early adopter pricing discussions with hospital systems and durable medical equipment suppliers.